{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:52:16Z","timestamp":1791996736962,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["313397"],"award-info":[{"award-number":["313397"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["313416"],"award-info":[{"award-number":["313416"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.omto.2020.04.001","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T01:59:59Z","timestamp":1586829599000},"page":"278-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity"],"prefix":"10.1016","volume":"17","author":[{"given":"Joanne A.","family":"Hammill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek M.","family":"Kwiecien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dvorkin-Gheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian W.C.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Bezverbnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Heslen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina F.","family":"Denisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Derocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Bramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2020.04.001_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.omto.2020.04.001_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib5","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J.\u00a0Clin. Oncol"},{"key":"10.1016\/j.omto.2020.04.001_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.omto.2020.04.001_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2020.04.001_bib8","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T\u00a0cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.04.001_bib9","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2020.04.001_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymthe.2016.11.011","article-title":"The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy","volume":"25","author":"Bedoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.04.001_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.04.001_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.04.001_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biol","volume":"25","author":"Lee","year":"2019","journal-title":"Blood Marrow Transplant"},{"key":"10.1016\/j.omto.2020.04.001_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2020.04.001_bib16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.04.001_bib17","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T\u00a0cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.04.001_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T\u00a0cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.04.001_bib19","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2020.04.001_bib20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T\u00a0cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.04.001_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T\u00a0cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omto.2020.04.001_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2020.04.001_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T\u00a0cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2020.04.001_bib26","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2020.04.001_bib27","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T\u00a0cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.04.001_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2020.04.001_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.omto.2020.04.001_bib30","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.04.001_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2020.04.001_bib32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2020.04.001_bib33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2020.04.001_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.omto.2020.04.001_bib35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2020.04.001_bib36","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/mt.2016.149","article-title":"Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy","volume":"24","author":"Smith","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.04.001_bib37","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in\u00a0vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T\u00a0cells: identifying a window of therapeutic opportunity?","volume":"191","author":"van der Stegen","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2020.04.001_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T\u00a0cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.omto.2020.04.001_bib39","series-title":"Treatment of cancer using humanized anti-cd19 chimeric antigen receptor. US patent application publication 20140271635 A1, filed March 15, 2014, and published September 18, 2014","author":"Brogdon","year":"2014"},{"key":"10.1016\/j.omto.2020.04.001_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2020.04.001_bib41","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T\u00a0cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2020.04.001_bib42","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2020.04.001_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4939-3801-8_11","article-title":"Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes","volume":"1458","author":"Hammill","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2020.04.001_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1287\/opre.2015.1361","article-title":"The Power of Optimization Over Randomization in Designing Experiments Involving Small Samples","volume":"63","author":"Bertsimas","year":"2015","journal-title":"Oper. Res."},{"key":"10.1016\/j.omto.2020.04.001_bib45","doi-asserted-by":"crossref","first-page":"26996","DOI":"10.1038\/srep26996","article-title":"The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays","volume":"6","author":"Breen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2020.04.001_bib46","series-title":"rgl: 3D Visualization Using OpenGL (v.0.100.54)","author":"Adler","year":"2020"},{"key":"10.1016\/j.omto.2020.04.001_bib47","series-title":"gplots: Various R Programming Tools for Plotting Data. (v.3.0.3)","author":"Warnes","year":"2020"},{"key":"10.1016\/j.omto.2020.04.001_bib48","first-page":"397","article-title":"limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor, R","author":"Smyth","year":"2005"},{"key":"10.1016\/j.omto.2020.04.001_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.omto.2020.04.001_bib50","first-page":"503","article-title":"Neuropathology of bouncer Long Evans, a novel dysmyelinated rat","volume":"50","author":"Kwiecien","year":"2000","journal-title":"Comp. Med."}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520300516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770520300516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:39:26Z","timestamp":1791995966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770520300516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"alternative-id":["S2372770520300516"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2020.04.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2020.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}